These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8431370)

  • 1. Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
    Philip PA; Carmichael J; Tonkin K; Buamah PK; Britton J; Dowsett M; Harris AL
    Br J Cancer; 1993 Feb; 67(2):379-82. PubMed ID: 8431370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex hormone levels in the serum of patients with pancreatic adenocarcinoma.
    Fyssas I; Syrigos KN; Konstandoulakis MM; Papadopoulos S; Milingos N; Anapliotou M; Waxman J; Golematis BC
    Horm Metab Res; 1997 Mar; 29(3):115-8. PubMed ID: 9137981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.
    Aydiner A; Kilic L; Yildiz I; Keskin S; Sen F; Kucucuk S; Karanlik H; Muslumanoglu M; Igci A
    Med Oncol; 2013 Mar; 30(1):354. PubMed ID: 23275115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer.
    Hofstra LS; Mourits MJ; de Vries EG; Mulder NH; Willemse PH
    Anticancer Res; 1999; 19(4C):3627-30. PubMed ID: 10629663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LH-RH analogue treatment in adenocarcinoma of the pancreas: a phase II study. Gruppo Ligure per lo Studio del Pancreas.
    Allegretti A; Lionetto R; Saccomanno S; Paganuzzi M; Onetto M; Martinoli C; Rollandi G; Marugo M; Fazzuoli L; Pugliese V
    Oncology; 1993; 50(2):77-80. PubMed ID: 8451039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
    Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M
    Anticancer Drugs; 1992 Feb; 3(1):3-8. PubMed ID: 1535804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen response in polycystic ovarian syndrome to FSH treatment after LHRH agonist suppression.
    Hamori M; Zwirner M; Clédon P; Tinneberg HR
    Int J Fertil; 1992; 37(3):171-5. PubMed ID: 1355764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.
    Levine D; Park K; Juretzka M; Esch J; Hensley M; Aghajanian C; Lewin S; Konner J; Derosa F; Spriggs D; Iasonos A; Sabbatini P
    Cancer; 2007 Dec; 110(11):2448-56. PubMed ID: 17918264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology.
    Buzzoni R; Biganzoli L; Bajetta E; Celio L; Fornasiero A; Mariani L; Zilembo N; Di Bartolomeo M; Di Leo A; Arcangeli G
    Br J Cancer; 1995 May; 71(5):1111-4. PubMed ID: 7734310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
    Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
    Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
    Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
    J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non-tumoral causes of androgen excess.
    d'Alva CB; Abiven-Lepage G; Viallon V; Groussin L; Dugue MA; Bertagna X; Bertherat J
    Eur J Endocrinol; 2008 Nov; 159(5):641-7. PubMed ID: 18708437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids.
    West CP; Lumsden MA; Hillier H; Sweeting V; Baird DT
    Hum Reprod; 1992 Mar; 7(3):328-32. PubMed ID: 1534089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients.
    Bajetta E; Zilembo N; Buzzoni R; Celio L; Zampino MG; Colleoni M; Oriana S; Attili A; Sacchini V; Martinetti A
    Oncology; 1994; 51(3):262-9. PubMed ID: 8196909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.